Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as an injectable solution (kit for reconstitution) for intravenous use. It is employed to visualize myocardial perfusion during single‑photon emission computed tomography, aiding the assessment of coronary artery disease and myocardial viability in adult patients. It is indicated for adult patients undergoing evaluation for coronary artery disease, myocardial ischemia, and viability prior to revascularization procedures.

GNH USA supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, diagnostic centres and clinics worldwide, ensuring reliable cold‑chain logistics and regulatory compliance.

Myoview is used in cardiac imaging to assess myocardial blood flow and detect coronary artery disease.

Myocardial perfusion imaging (SPECT): provides quantitative images of regional blood flow to identify perfusion defects. Evaluation of coronary artery disease: helps detect ischemic regions and guide therapeutic decisions. Assessment of myocardial viability: distinguishes viable myocardium from scar tissue to inform revascularization planning.

Adverse reactions to Myoview are generally related to the radiopharmaceutical nature of the product and the intravenous administration.

Common Side Effects: - Nausea: mild, transient nausea occurring shortly after injection. - Flushing: temporary facial or upper body flushing. - Headache: mild to moderate headache reported post‑administration. - Injection site pain: brief discomfort at the venipuncture site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Severe hypotension: marked drop in blood pressure that may need treatment. - Radiation‑induced skin reaction: localized skin changes at the injection site due to radiation exposure.

Prior to using Myoview, several safety considerations should be reviewed. - Renal impairment: assess renal function before administration as clearance may be reduced. - Pregnancy: use only if the diagnostic benefit outweighs potential fetal risk. - Breastfeeding: consider discontinuation of breastfeeding or assess infant exposure risk. - Concurrent radiopharmaceuticals: avoid co‑administration to prevent competitive binding. - Allergy to technetium: contraindicated in patients with known hypersensitivity to technetium‑99m compounds. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Myoview may interact with certain drugs or agents that affect radiotracer distribution or imaging interpretation.

Major Interactions (Avoid): - Other Tc‑99m labeled agents: may compete for myocardial uptake and reduce image quality. - High‑dose iodinated contrast: can interfere with tracer distribution and compromise SPECT results.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may alter myocardial perfusion patterns and affect tracer uptake. - Calcium channel blockers: can modify coronary blood flow influencing imaging outcomes. - Thyroid disorders: abnormal thyroid function may affect technetium kinetics.